This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sampaio, C. Articles by Castro-Caldas, A. Search for Related Content PubMed PubMed Citation Articles by Sampaio, C. Articles by Castro-Caldas, A. Social Bookmarking                         What's this?

Botulinum toxin type A for the treatment of arm and hand spasticity in stroke patients

Department of Pharmacology and Therapeutics, Hospital de Santa Maria

Joaquim J Ferreira

Department of Neurology, Hospital de Santa Maria, Lisbon

Ana A Pinto

Department of Neurology, Hospital de Santa Maria, Lisbon

Manuela Crespo

Department of Neurology, Hospital de Santa Maria, Lisbon

José M Ferro

Department of Neurology, Hospital de Santa Maria, Lisbon

Alexandre Castro-Caldas

Department of Neurology, Hospital de Santa Maria, Lisbon

Background: Focal spasticity can be a major drawback in the rehabilitation of stroke patients. Previous studies suggest a beneficial effect for botulinum toxin A (BTX-A) for relief of spasticity.

Objective: To evaluate the safety and efficacy of BTX-A in the treatment of spasticity in a homogeneous group of stroke patients.

Methods: In this phase III open label trial 19 stroke patients stable for at least six months were enrolled (mean age 53.1 (SD 3.27) years; range 26-72). There were 16 males and 4 females.

Assessments: Clinical (Ashworth spasticity rating scale, scores for joint mobility, pain and frequency of spasms, Frenchay arm test (FAT)) and subjective (semi-quantitative rating scale filled out by the patient). Only hand and finger flexors were injected. The maximum dosage was 150 U BOTOX® (25 U/muscle), the mean dosage was 92.1 ± 31.6 U BOTOX®.

Results: Ashworth rating scale and joint mobility scores improved from a median value of 2 at baseline to a median value of 1 one month after treatment, FAT scores also improved from a median value of 0 at baseline to a median value of 1 one month after treatment (Kruskall-Wallis test p < 0.01). Two-thirds of the patients rated their functional improvement as none or mild.

Conclusions: Our study confirmed that BTX-A has an anti-spastic effect but its functional impact needs further evaluation.

Clinical Rehabilitation, Vol. 11, No. 1, 3-7 (1997)
DOI: 10.1177/026921559701100102


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. Ozcakir and K. Sivrioglu Botulinum Toxin in Poststroke Spasticity Clin. Med. Res., June 1, 2007; 5(2): 132 - 138. [Abstract] [Full Text] [PDF]

				P. Raghavan, E. Petra, J. W. Krakauer, and A. M. Gordon Patterns of Impairment in Digit Independence After Subcortical Stroke J Neurophysiol, January 1, 2006; 95(1): 369 - 378. [Abstract] [Full Text] [PDF]

				M. F. Gordon, A. Brashear, E. Elovic, D. Kassicieh, C. Marciniak, J. Liu, C. Turkel, and for the BOTOX Poststroke Spasticity Study Group Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke Neurology, November 23, 2004; 63(10): 1971 - 1973. [Abstract] [Full Text] [PDF]

				A. Brashear, M. F. Gordon, E. Elovic, V. D. Kassicieh, C. Marciniak, M. Do, C.-H. Lee, S. Jenkins, C. Turkel, and the Botox Post-Stroke Spasticity Study Group Intramuscular Injection of Botulinum Toxin for the Treatment of Wrist and Finger Spasticity after a Stroke N. Engl. J. Med., August 8, 2002; 347(6): 395 - 400. [Abstract] [Full Text] [PDF]

				E. C DAVIS and M. P BARNES Botulinum toxin and spasticity J. Neurol. Neurosurg. Psychiatry, August 1, 2000; 69(2): 143 - 147. [Full Text] [PDF]

				B. B Bhakta, J A. Cozens, M A. Chamberlain, and J. M Bamford Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial J. Neurol. Neurosurg. Psychiatry, August 1, 2000; 69(2): 217 - 221. [Abstract] [Full Text] [PDF]

				S J Smith, E Ellis, S White, and A P Moore A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury Clinical Rehabilitation, January 1, 2000; 14(1): 5 - 13. [Abstract] [PDF]

				A D Pandyan, G R Johnson, C I M Price, R H Curless, M P Barnes, and H Rodgers A review of the properties and limitations of the Ashworth and modified Ashworth Scales as measures of spasticity Clinical Rehabilitation, May 1, 1999; 13(5): 373 - 383. [Abstract] [PDF]

				S. Hesse, F. Reiter, M. Konrad, and M. T Jahnke Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double-blind, placebo-controlled trial Clinical Rehabilitation, May 1, 1998; 12(5): 381 - 388. [Abstract] [PDF]